a developer of biomedical research products in the field of stem cells and regenerative medicine
Industry Biotechnology
A.I.dvisor tells us that ERNA and GMAB have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ERNA and GMAB's prices will move in lockstep.
Ticker / NAME | Correlation To ERNA | 1D Price Change % | ||
---|---|---|---|---|
ERNA | 100% | +0.99% | ||
GMAB - ERNA | 27% Poorly correlated | -2.22% | ||
LXRX - ERNA | 26% Poorly correlated | -2.75% | ||
ARVN - ERNA | 26% Poorly correlated | -1.66% | ||
ALRN - ERNA | 26% Poorly correlated | -7.28% | ||
VSTM - ERNA | 25% Poorly correlated | +0.73% | ||
More |
Ticker / NAME | Correlation To ERNA | 1D Price Change % |
---|---|---|
ERNA | 100% | +0.99% |
regenerative medicine theme (2 stocks) | 52% Loosely correlated | -5.33% |
stem cells theme (21 stocks) | 16% Poorly correlated | -3.36% |
medical research theme (126 stocks) | 13% Poorly correlated | -1.85% |
medical service theme (154 stocks) | 13% Poorly correlated | -1.97% |
biological theme (25 stocks) | 3% Poorly correlated | -1.51% |